The cell cycle and cancer
暂无分享,去创建一个
[1] T. Mikkelsen,et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Stoeber,et al. Cdc 6 protein causes premature entry into S phase in a mammalian cell-free system , 2013 .
[3] Jorge S. Reis-Filho,et al. Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement , 2011, Journal of the National Cancer Institute.
[4] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[5] J. Bogers,et al. BD-ProExC as Adjunct Molecular Marker for Improved Detection of CIN2+ after HPV Primary Screening , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[6] L. Hunter,et al. ProExC Triage of Atypical Glandular Cells on Liquid-Based Cervical Cytology Specimens , 2011, Journal of lower genital tract disease.
[7] W. Fisher. The Promise of a Personalized Genomic Approach to Pancreatic Cancer and Why Targeted Therapies Have Missed the Mark , 2011, World Journal of Surgery.
[8] P. Russell,et al. Hsk1 kinase and Cdc45 regulate replication stress-induced checkpoint responses in fission yeast , 2010, Cell cycle.
[9] M. Trotter,et al. Molecular architecture of the DNA replication origin activation checkpoint , 2010, The EMBO journal.
[10] Richard Sainsbury,et al. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. , 2010, The American journal of pathology.
[11] A. Montagnoli,et al. Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy , 2010, Clinical Cancer Research.
[12] G. Williams,et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments , 2010, British Journal of Cancer.
[13] K. Labib. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? , 2010, Genes & development.
[14] Hisao Masai,et al. Eukaryotic chromosome DNA replication: where, when, and how? , 2010, Annual review of biochemistry.
[15] E. Small,et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Zeegers,et al. Biomarkers in bladder cancer , 2010, BJU international.
[17] W. Mason,et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[19] Bruce Stillman,et al. The Dbf4-Cdc7 kinase promotes S phase by alleviating an inhibitory activity in Mcm4 , 2009, Nature.
[20] F. Giles,et al. Cdc7 kinase - a new target for drug development. , 2010, European journal of cancer.
[21] S. Giordano,et al. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy , 2010, Molecular Cancer.
[22] K. Stoeber,et al. DNA Replication Licensing Factors and Aneuploidy Are Linked to Tumor Cell Cycle State and Clinical Outcome in Penile Carcinoma , 2009, Clinical Cancer Research.
[23] F. Penault-Llorca,et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] I. Ellis,et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.
[25] M. Stratton,et al. The cancer genome , 2009, Nature.
[26] Kai Stoeber,et al. Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma , 2009, Clinical Cancer Research.
[27] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[29] M Loddo,et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer , 2009, British Journal of Cancer.
[30] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[31] D. Wilbur,et al. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. , 2009, Archives of pathology & laboratory medicine.
[32] A. Nassar,et al. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. , 2008, American journal of clinical pathology.
[33] J. Julian Blow,et al. Replication licensing and cancer — a fatal entanglement? , 2008, Nature Reviews Cancer.
[34] J. Im,et al. ATR-dependent Activation of p38 MAP Kinase Is Responsible for Apoptotic Cell Death in Cells Depleted of Cdc7* , 2008, Journal of Biological Chemistry.
[35] A. Isacchi,et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. , 2008, Nature chemical biology.
[36] N. Kakusho,et al. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint , 2008, Oncogene.
[37] Janet A. Dunn,et al. tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC) , 2008 .
[38] G. Williams,et al. Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates , 2008, British Journal of Cancer.
[39] R. Bernards,et al. Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.
[40] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[41] Xin Quan Ge,et al. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. , 2007, Genes & development.
[42] R. Sclafani,et al. Cell cycle regulation of DNA replication. , 2007, Annual review of genetics.
[43] K. Stoeber,et al. Cell cycle markers in clinical oncology. , 2007, Current opinion in cell biology.
[44] Amy Freeland,et al. Reduced Mcm2 Expression Results in Severe Stem/Progenitor Cell Deficiency and Cancer , 2007, Stem cells.
[45] Anindya Dutta,et al. Mechanisms to control rereplication and implications for cancer. , 2007, Current opinion in cell biology.
[46] Wim H van Harten,et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). , 2007, The Lancet. Oncology.
[47] Dimitris Kletsas,et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. , 2007, Cancer research.
[48] K. Stoeber,et al. Cdc6 is a rate-limiting factor for proliferative capacity during HL60 cell differentiation. , 2007, Experimental cell research.
[49] J. Ledermann,et al. DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma , 2007, Clinical Cancer Research.
[50] C. Sotiriou,et al. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.
[51] K. Labib,et al. A key role for the GINS complex at DNA replication forks. , 2007, Trends in cell biology.
[52] E. Salmon,et al. The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.
[53] Stefan Michiels,et al. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? , 2007, European journal of cancer.
[54] B. Tye,et al. A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice , 2007, Nature Genetics.
[55] J. Coindre. Grading of soft tissue sarcomas: review and update. , 2009, Archives of pathology & laboratory medicine.
[56] D. Clark,et al. Detection of cervical high‐grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™ C) , 2006, Cancer.
[57] Meenakshi Singh,et al. Validation of a novel immunocytochemical assay for topoisomerase II‐α and minichromosome maintenance protein 2 expression in cervical cytology , 2006, Cancer.
[58] Bruce Stillman,et al. Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-mediated mechanism to promote S phase progression. , 2006, Molecular cell.
[59] J. Nevins,et al. Linking oncogenic pathways with therapeutic opportunities , 2006, Nature Reviews Cancer.
[60] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[61] D. Roop,et al. Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis , 2006, Oncogene.
[62] M. Botchan,et al. Isolation of the Cdc45/Mcm2–7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase , 2006, Proceedings of the National Academy of Sciences.
[63] A. Montagnoli,et al. Identification of Mcm2 Phosphorylation Sites by S-phase-regulating Kinases* , 2006, Journal of Biological Chemistry.
[64] P. Klatt,et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus , 2006, Nature.
[65] Ricky D. Edmondson,et al. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks , 2006, Nature Cell Biology.
[66] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[67] M. Barbacid,et al. Is Cyclin D1-CDK4 kinase a bona fide cancer target? , 2006, Cancer cell.
[68] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[69] T. Pandita,et al. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53 , 2005, Oncogene.
[70] J Julian Blow,et al. The chromosome cycle: coordinating replication and segregation , 2005, EMBO reports.
[71] Anindya Dutta,et al. Right Place, Right Time, and Only Once: Replication Initiation in Metazoans , 2005, Cell.
[72] J. Diffley,et al. CDKs Promote DNA Replication Origin Licensing in Human Cells by Protecting Cdc6 from APC/C-Dependent Proteolysis , 2005, Cell.
[73] P. Korkolopoulou,et al. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. , 2005, Human pathology.
[74] J. Julian Blow,et al. Preventing re-replication of chromosomal DNA , 2005, Nature Reviews Molecular Cell Biology.
[75] M. J. van de Vijver,et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] K. Stoeber,et al. Mcm2, Geminin, and KI67 Define Proliferative State and are Prognostic Markers in Renal Cell Carcinoma , 2005, Clinical Cancer Research.
[77] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[78] Michael A. Gonzalez,et al. Control of DNA replication and its potential clinical exploitation , 2005, Nature Reviews Cancer.
[79] K. Stoeber,et al. Mcm 2 , Geminin , and KI 67 Define Proliferative State and Are PrognosticMarkers in Renal Cell Carcinoma , 2005 .
[80] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[81] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] K. Stoeber,et al. DNA replication licensing in somatic and germ cells , 2004, Journal of Cell Science.
[83] Jiri Bartek,et al. Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.
[84] K. Stoeber,et al. Molecular structure of human geminin , 2004, Nature Structural &Molecular Biology.
[85] A. Montagnoli,et al. Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells , 2004, Cancer Research.
[86] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[87] Ituro Inoue,et al. Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor , 2004, Oncogene.
[88] G. Williams,et al. Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates , 2004, British Journal of Cancer.
[89] P. Brown,et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[90] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[91] Ituro Inoue,et al. Regulation of Geminin and Cdt1 expression by E2F transcription factors , 2004, Oncogene.
[92] Michael A. Gonzalez,et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Xiaohua Wu,et al. The SCFSkp2 Ubiquitin Ligase Complex Interacts with the Human Replication Licensing Factor Cdt1 and Regulates Cdt1 Degradation* , 2003, Journal of Biological Chemistry.
[94] M. West,et al. Gene expression phenotypic models that predict the activity of oncogenic pathways , 2003, Nature Genetics.
[95] Axel Benner,et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. , 2003, Cancer research.
[96] D. Lane,et al. Cell type-specific responses of human cells to inhibition of replication licensing , 2002, Oncogene.
[97] K. Arai,et al. A 63-Base Pair DNA Segment Containing an Sp1 Site but Not a Canonical E2F Site Can Confer Growth-dependent and E2F-mediated Transcriptional Stimulation of the Human ASKGene Encoding the Regulatory Subunit for Human Cdc7-related Kinase* , 2002, The Journal of Biological Chemistry.
[98] K. Stoeber,et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. , 2002, Journal of the National Cancer Institute.
[99] J. Kutok,et al. Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. , 2002, The American journal of pathology.
[100] C. Ball,et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.
[101] T. Hunt,et al. Minichromosome maintenance (MCM) proteins may be pre-cancer markers , 2002, Gut.
[102] K Stoeber,et al. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa , 2002, Gut.
[103] D. Gutmann,et al. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo , 2002, Oncogene.
[104] D. Fremont,et al. Oncogenic potential of the DNA replication licensing protein CDT1 , 2002, Oncogene.
[105] J. Blow,et al. Replication licensing — Origin licensing: defining the proliferative state? , 2002 .
[106] C. Allis,et al. Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases , 2002, Molecular and Cellular Biology.
[107] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[108] J. Blow,et al. Replication licensing--defining the proliferative state? , 2002, Trends in cell biology.
[109] M. Barbacid,et al. To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.
[110] G. Bepler,et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] K Stoeber,et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[112] M. Blagosklonny,et al. Exploiting cancer cell cycling for selective protection of normal cells. , 2001, Cancer research.
[113] G. Williams,et al. DNA replication licensing and human cell proliferation. , 2001, Journal of cell science.
[114] J. Diffley,et al. Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? , 2001, Current opinion in genetics & development.
[115] M. Méchali,et al. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin , 2001, Nature Cell Biology.
[116] Erich A. Nigg,et al. Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.
[117] J. Harbour,et al. The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.
[118] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[119] K. Stoeber,et al. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine , 1999, The Lancet.
[120] G. Williams,et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[121] G. Williams,et al. Clinical applications of a novel mammalian cell-free DNA replication system. , 1999, British journal of cancer.
[122] Kiyoshi Ohtani,et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F , 1999, Oncogene.
[123] C. Allis,et al. Phosphorylation of Histone H3 Is Required for Proper Chromosome Condensation and Segregation , 1999, Cell.
[124] K. Stoeber,et al. Cdc6 protein causes premature entry into S phase in a mammalian cell‐free system , 1998, The EMBO journal.
[125] G. Williams,et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[126] J. Diffley,et al. Nucleotide-dependent prereplicative complex assembly by Cdc6p, a homolog of eukaryotic and prokaryotic clamp-loaders. , 1998, Molecular cell.
[127] R. Knippers,et al. Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. , 1998, Experimental cell research.
[128] J. Nevins,et al. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[129] R. Weinberg,et al. The restriction point and control of cell proliferation. , 1997, Current opinion in cell biology.
[130] A. Murray,et al. The Cell Cycle: An Introduction , 1993 .
[131] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[132] M. Loeffler,et al. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. , 1990, Development.
[133] L. Hartwell,et al. Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.
[134] F. Watt,et al. Stem cells: the generation and maintenance of cellular diversity. , 1989, Development.
[135] A. Zetterberg,et al. Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.